Innoscripta's Strategic Pivot: A New Frankfurt Hub to Fuel International Ambitions

Innoscripta launches a Frankfurt hub as part of its 2026 global push, aiming for €140M revenue and €80M EBIT. Shares show tentative recovery after a 10% weekly gain.

Innoscripta is making a definitive strategic move with the launch of a new operational base in Frankfurt. This initiative is a core component of the company's plan to enter the international arena by 2026. With ambitious targets set, market participants are closely monitoring whether this expansion can provide a durable reversal for the company's shares, which have been under pressure.

Financial Targets and Strategic Foundation

Central to Innoscripta's strategy is growth beyond its domestic market, with the Frankfurt location serving as a pivotal hub within the European financial sector. Management has outlined confident projections for the current fiscal year, forecasting consolidated group revenue to reach a minimum of €140 million. This target underscores their belief in the scalability of the underlying business model.

The planned operational milestones and financial objectives are clear:
* A new Frankfurt office opening on March 19, 2026.
* Targeted consolidated revenue of at least €140 million.
* An expected EBIT (Earnings Before Interest and Taxes) of no less than €80 million.

These forecasts are predicated on sustained high demand and a stable regulatory environment. The stated EBIT goal of €80 million particularly highlights the company's focus on achieving profitability even during a period of significant expansion.

Share Price Shows Tentative Signs of Recovery

On the trading floor, Innoscripta's equity is displaying initial signals of a potential turnaround following a challenging period. The stock advanced nearly 10% last week, closing Friday's session at €69.50. This move allowed it to recover some ground from its annual low of €62.30. Despite this recent gain, the share price remains down approximately 21% since the start of the year.

Technical indicators provide a mixed picture. The gap to the 50-day moving average, currently at €73.65, has recently narrowed to around 5.6%, though a decisive and sustained break above this level has not yet occurred. With a Relative Strength Index (RSI) reading of 33.7, the shares, while still near oversold territory, suggest that selling pressure may be starting to abate.

The market's attention is now firmly fixed on the company's execution of its announced expansion plans. If Innoscripta can substantiate its ambitious €80 million EBIT target through tangible project successes in the coming months, it may establish a foundation for a longer-term recovery toward its 52-week high of €132.40.